SeeThruEquity Initiates Research Coverage on Cardax, Inc. with a Target Price of $1.00
ACCESSWIRE - Mon Oct 06, 8:06AM CDT
New York, NY / ACCESSWIRE / October 6, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Cardax, Inc. (OTCQB: CDXI), Cardax is a development stage, life sciences company focused on introducing nutraceutical and pharmaceutical products aimed at reducing inflammation and oxidative stress.
Cardax Appoints Former Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim Executives as Directors
Business Wire - Tue Jun 17, 7:01AM CDT
Cardax, Inc. ("Cardax"
OXGN: 2.39 (+0.01), ACT: 237.53 (-1.50), LXRX: 1.37 (-0.04), ONVO: 6.28 (-0.20), IDIX: 24.50 (+0.05), BMY: 53.92 (-0.28), NVS: 91.71 (-0.64)